{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.65","value":"28.76"},{"groupId":"OG001","spread":"39.52","value":"42.48"},{"groupId":"OG002","spread":"33.75","value":"45.17"},{"groupId":"OG003","spread":"130.02","value":"25.58"},{"groupId":"OG004","spread":"58.10","value":"-9.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"48"}],"units":"Participants"}],"description":"The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of \"X\" has improvement of at least \"X%\" in tender and swollen joints and a median improvement of at least \"X%\" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.","dispersionType":"Standard Deviation","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) 4 capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All participants who received any study drug in Part A and had baseline and at least one post baseline ACR-N response measure. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 weeks","title":"Mean Value of ACR-N Response (Part A)","type":"SECONDARY","unitOfMeasure":"percentage of responders"}